Breaking News

Family Dollar Board Rejects Proposal From Dollar General
Tweet TWEET

PRA Voted "Best CRO" in Asia

                         PRA Voted "Best CRO" in Asia

  PR Newswire

  RALEIGH, North Carolina, March 25, 2013

               - Awarded at BioPharma Asia Industry Awards 2013

RALEIGH, North Carolina, March 25, 2013 /PRNewswire/ --PRA, a leading
clinical research organization, today announced it was voted "Best CRO" for
the 3rd annual BioPharma Asia Industry Awards 2013. The winner was announced
March 19 at an awards dinner in Singapore.

"We are deeply honored to have been voted 'Best CRO'," said Kent Thoelke, PRA
executive vice president, Scientific and Medical Affairs. "We have been
working hard to continually meet the growing needs of our clients in this
region, and I'm confident that we will continue to enhance our capability in
the Asia Pacific region while ensuring we provide high-quality services."

"PRA has been strategically expanding its operations and has achieved several
key expansion milestones in Asia Pacific," said Helen Neal, PRA director,
Clinical Operations Asia Pacific. "We recently formed a joint venture with
Wuxi PharmaTech in China, opened offices in Singapore, and expanded operations
in South Korea."

Organized by Terrapinn, the awards honor and generate public recognition of
the efforts, accomplishments and positive contributions of organizations and
individuals in Asia's biopharmaceutical industry. They identify and reward
those who demonstrate an ability to succeed, continually set standards of
excellence, and who will be the future of the biopharmaceutical industry.

There are nine award categories: Best LSP Award; Best Contract Research
Organization Award; Best Contract Manufacturing Organization Award; Most
Innovative Asian Biotech Award; Asian Executive of the Year; Woman Executive
of the Year; Best Manufacturing Solution Provider Award; Best Drug Pipeline
Award; and Pharma Company of the Year.

About PRA

PRA is transforming clinical trials through our people, innovation and
transparency. PRA provides personalized service customized to the unique
requirements of each study. We support our global reach and innovative
approach through flexible and reliable service, delivered by skilled employees
dedicated to ensuring that sponsors achieve their long-term goals.

We serve our clients across all phases of pharmaceutical and biotech drug
development by combining therapeutic and operational expertise with local
knowledge. Offering services in 80+ countries and serving sponsors for 35+
years, we have amassed a level of expertise that has enabled us to work on a
variety of compounds, ranging from niche treatments and therapies to
blockbuster drugs. But at PRA, we are looking to the future, not the past. Our
increasingly forward-thinking approach to transforming the clinical trial
landscape will continue to make a difference to healthcare patients around the
world.

To learn more about PRA, please visit praintl.com , email
endpoints@praintl.com or call our Global Headquarters.

Website: http://www.praintl.com
Contact: Roger Boutin, Senior Director - Marketing, PRA, +1-434-951-3924
 
Press spacebar to pause and continue. Press esc to stop.